Currently, only Arizona, Delaware, and Idaho cover weight-loss medications, though nine state Medicaid programs (California, Connecticut, Delaware, Michigan, Minnesota, Pennsylvania, Rhode Island, Virginia, and Wisconsin) have added Wegovy to their preferred drug lists lists of drugs that states encourage their providers to prescribe over others as a mechanism to negotiate higher supplemental rebates
[30] The discovery of GLP-1's extremely short half-life meant that it was impossible to develop into a drug
Evidences suggests that supplementing L-carnitine in parenteral nutrition (PN) regimens can significantly enhance fatty acid metabolism in neonates (12, 13)
It may not be suitable for those with kidney or liver issues, type 1 diabetes, or a history of diabetic ketoacidosis